Retrophin Inc (NASDAQ:RTRX) SVP William E. Rote sold 1,250 shares of the company’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $21.44, for a total transaction of $26,800.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

William E. Rote also recently made the following trade(s):

  • On Tuesday, February 19th, William E. Rote sold 2,500 shares of Retrophin stock. The stock was sold at an average price of $21.48, for a total transaction of $53,700.00.

RTRX stock traded down $0.16 during trading on Wednesday, hitting $20.95. 239,700 shares of the company’s stock traded hands, compared to its average volume of 337,524. Retrophin Inc has a 52 week low of $19.77 and a 52 week high of $33.00. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $889.30 million, a P/E ratio of -13.97 and a beta of 1.38.

A number of hedge funds have recently added to or reduced their stakes in RTRX. Bank of America Corp DE lifted its position in Retrophin by 114.4% during the fourth quarter. Bank of America Corp DE now owns 1,223,705 shares of the biopharmaceutical company’s stock valued at $27,693,000 after purchasing an additional 652,895 shares during the last quarter. Macquarie Group Ltd. lifted its position in Retrophin by 17.6% during the fourth quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock valued at $51,278,000 after purchasing an additional 339,588 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Retrophin by 21.6% during the third quarter. The Manufacturers Life Insurance Company now owns 1,845,403 shares of the biopharmaceutical company’s stock valued at $53,018,000 after purchasing an additional 327,194 shares during the last quarter. Two Sigma Investments LP lifted its position in Retrophin by 247.9% during the fourth quarter. Two Sigma Investments LP now owns 300,873 shares of the biopharmaceutical company’s stock valued at $6,809,000 after purchasing an additional 214,392 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its position in Retrophin by 30.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 777,520 shares of the biopharmaceutical company’s stock valued at $17,595,000 after purchasing an additional 182,318 shares during the last quarter.

RTRX has been the subject of a number of research reports. Jefferies Financial Group initiated coverage on shares of Retrophin in a research report on Tuesday, October 30th. They set a “buy” rating and a $44.00 target price for the company. Nomura initiated coverage on shares of Retrophin in a research report on Monday, November 19th. They set a “buy” rating and a $57.00 price objective for the company. ValuEngine lowered shares of Retrophin from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 17th. BidaskClub lowered shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Friday, January 11th. Finally, Zacks Investment Research lowered shares of Retrophin from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 8th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $48.00.

WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.watchlistnews.com/insider-selling-retrophin-inc-rtrx-svp-sells-1250-shares-of-stock/2835776.html.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.